BioInvent says FDA grants Fast Track designation for BI-1808 in ovarian cancer

Reuters2026/08/07 08:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA granted Fast Track designation for BioInvent’s BI-1808 with pembrolizumab in ovarian cancer.
ASCO 2026 data showed 24% confirmed ORR, 56% DCR in advanced platinum-resistant ovarian cancer.
Cohort expansion continues in high-grade serous, clear cell subtypes; next data readout expected in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioInvent says FDA grants Fast Track designation for BI-1808 in ovarian cancer

You may also like

Crypto prices